Embecta completes acquisition of Owen Mumford for £100M upfront plus up to £50M earnout

Embecta Corp.

Acquisition completed May 15, 2026; Owen Mumford is a UK-based medical device and drug-delivery technology manufacturer.
Upfront cash payment of £100M at closing; up to £50M additional based on Aidaptus auto-injector sales through June 2029.
Strategic move to transform embecta into a broad-based medical supplies company serving obesity, diabetes, autoimmune, and anaphylaxis markets.
Adds differentiated drug-delivery platform with Aidaptus next-generation auto-injector and strong IP portfolio.
Combines Owen Mumford's device design, molding, and assembly with embecta's global commercial infrastructure and manufacturing scale.

item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.